Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years

The treatments could help hundreds of thousands of men worldwide stave off pain and chemotherapy, but researchers don ’ t yet know if they will extend lives.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Prostate Cancer Source Type: news

Related Links:

AbstractCannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in several physiological processes is well known, such as in energy balance, appetite stimulation, blood pressure, pain modulation, embryogenesis, nausea and vomiting control, memory, learning and immune response, among others, as well as in pathological conditions where it exerts a protective role in the ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Authors: Rosino A, Ballester I, Tudela J, González-Billalabeitia E Abstract Prostate cancer is the second mortality cause among males with cancer. Patients with metastatic castration resistant prostate cancer (mCRPC) essentially die due to tumor progression in a castration resistance situation. Docetaxel based chemotherapy was the first therapeutic strategy that demonstrated a survival increase, in addition to pain decrease, increase in tumor responses and quality of life benefit, and it currently continues being useful after the incorporation of new therapies for the treatment of mCRPC. Cabazitaxel, a taxan...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Prostate cancer metastases are common, especially in the regional lymph nodes and bone tissues, however, are rare in the jaw. A 78-year-old man was referred by an oncology service for complaints of pain in the mandible. The patient had a history of prostatic adenocarcinoma treated with radiotherapy 16 years prior. Liver and pulmonary metastases were detected 1 year ago, and the patient is currently in chemotherapy treatment. A physical exam revealed a diffuse tumor mass involving all of the lower dental arches with buccal, lingual growth.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: Oral and Maxillofacial Pathology Source Type: research
Authors: Parghane RV, Basu S Abstract Transformed small cell carcinoma of prostate represents a distinct tumor biology from the adenocarcinoma counterpart and penile metastasis from prostate cancer is a rare entity. Unique features of this transformation include unresponsiveness to hormonal therapy and presence of visceral metastases, which can demonstrate hypermetabolism on 18F-FDG PET/CT. The importance of dual tracer PET/CT using 68Ga-PSMA and 18F-FDG is illustrated in metastatic prostatic adenocarcinoma (Gleason's score 4+3=7) with previous history of bilateral orchidectomy, chemotherapy and radiotherapy, who p...
Source: Journal of Nuclear Medicine Technology - Category: Nuclear Medicine Tags: J Nucl Med Technol Source Type: research
From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
Source: Stayin' Alive - Category: American Health Source Type: blogs
ConclusionsEnzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment.Patient summaryPatients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: European Urology, Volume 74, Issue 1Author(s): Kurt Miller, Joan Carles, Jürgen E. Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D. Brookman-MayAbstractBackgroundIn the COU-AA-302 study (NCT00887198), abiraterone acetate plus prednisone (AAP) significantly improved outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) versus prednisone alone. Baseline clinical parameters predicting that treatment response could help inform clinical decisions were explored.ObjectiveTo identify patients who derive the greatest clinical benefit from AAP treatment.Design, ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 2 June 2018Source: Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)Author(s): J. Orcajo-Rincon, A.P. Caresia-Aróztegui, M. del Puig Cózar-Santiago, J.R. García-Garzón, M. de Arcocha-Torres, R.C. Delgado-Bolton, M.J. García-Velloso, S. Alvarez-Ruiz, A.M. García-VicenteAbstractBone metastatic disease is the main cause of morbidity/mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the ...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
ConclusionsEnzalutamide showed antitumour activity in some patients with mCRPC who had previously progressed following ≥24 wk of abiraterone acetate plus prednisone treatment.Patient summaryPatients with mCRPC who progressed on previous abiraterone acetate plus prednisone treatment, with or without prior chemotherapy, received enzalutamide. Although cross-resistance between the two agents was observed in a majority of patients, some still benefited from enzalutamide treatment.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: European Urology, Volume 74, Issue 1Author(s): Kurt Miller, Joan Carles, Jürgen E. Gschwend, Hendrik Van Poppel, Joris Diels, Sabine D. Brookman-MayAbstractBackgroundIn the COU-AA-302 study (NCT00887198), abiraterone acetate plus prednisone (AAP) significantly improved outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) versus prednisone alone. Baseline clinical parameters predicting that treatment response could help inform clinical decisions were explored.ObjectiveTo identify patients who derive the greatest clinical benefit from AAP treatment.Design, ...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Pain | Prostate Cancer